天津医药 ›› 2016, Vol. 44 ›› Issue (2): 129-132.doi: 10.11958/20150125

• 述评 •    下一篇

血脂管理进展及思考

孙根义   

  1. 天津市胸科医院心内科
  • 收稿日期:2015-08-25 修回日期:2015-09-29 出版日期:2016-02-15 发布日期:2016-02-15
  • 通讯作者: 孙根义 E-mail:sungenyi@sina.com

Progress and thinking on the management of lipids

SUN Genyi   

  1. Tianjin Chest Hospital, Tianjin 300222, China
  • Received:2015-08-25 Revised:2015-09-29 Published:2016-02-15 Online:2016-02-15
  • Contact: SUN Genyi E-mail:sungenyi@sina.com

摘要:  动脉粥样硬化 (AS) 是冠心病、 缺血性脑卒中和外周血管疾病 (动脉粥样硬化性心血管疾病, ASCVD) 的病理基础, 血胆固醇水平与 ASCVD 发病风险密切相关。中国心血管病患病率和死亡率呈上升趋势。ASCVD 防治任务艰巨。血脂管理的目标是降低 ASCVD 风险。非高密度脂蛋白胆固醇 (非 HDL-C) 包括所有致 AS 脂蛋白胆固醇,非 HDL-C 与低密度脂蛋白胆固醇 (LDL-C) 并列为血脂管理干预靶标可能更为适合。依据风险评估, 设定血脂达标值适用于中国临床。生活方式干预是血脂管理的基础, 综合干预各项危险因素方可有效防治 ASCVD。

关键词: 动脉硬化, 胆固醇, 动脉粥样硬化性心血管疾病, 血脂管理

Abstract: Atherosclerosis is the pathological basis of coronary heart disease, ischemic stroke and peripheral vascular disease (atherosclerotic cardiovascular disease, ASCVD). Blood cholesterol levels are closely related to ASCVD. The prevalence and mortality of cardiovascular disease are increasing in China, which is a difficult task. The lipid management goal is to reduce the risk of ASCVD. Atherogenic cholesterol-non-high-density lipoprotein cholesterol (non-HDL-C) and low-density lipoprotein cholesterol (LDL-C) are used as the primary targets of therapy, which may be more appropriate for lipid management setting dislipidaemia value applied to Chinese clinic. Lifestyle intervention is the basis of lipid management. Effective prevention and treatment of ASCVD require the comprehensive intervention of risk factors.

Key words: arteriosclerosis, cholesterol, atherosclerotic cardiovascular disease, lipid management